key: cord-0703649-dnqi38sb authors: Rees, April; Turner, Steve; Thornton, Catherine A. title: Potential protective effects of breast milk and amniotic fluid against novel coronavirus SARS‐CoV‐2 through decoy receptors date: 2021-10-11 journal: Pediatr Allergy Immunol DOI: 10.1111/pai.13672 sha: 5df5ae4e2bde43e9b26f857a20d6268927f21c76 doc_id: 703649 cord_uid: dnqi38sb Infection of pregnant women during previous coronavirus mediated pandemics such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), were associated with high rates of fetal and maternal demise. However, the characteristics of COVID-19 in pregnant and non-pregnant women are very similar and while severe COVID-19 in pregnancy brings increased risk of preterm birth and intensive care admission 1 . Infection of pregnant women during previous coronavirus-mediated pandemics, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), was associated with high rates of fetal and maternal demise. However, the characteristics of COVID-19 in pregnant and non-pregnant women are very similar, and while severe COVID-19 in pregnancy brings increased risk of preterm birth and intensive care admission, 1 most pregnant women, be they symptomatic or asymptomatic for SARS-CoV-2 infection, do not experience severe complications in pregnancy. 2 Similarly, cases of SARS-CoV-2 vertical transmission are rare and there is low risk of serious disease for the neonate. 3 Understanding the mechanisms of resilience against severe COVID-19 in pregnant women and the newborn is critical to ensure ongoing vigilance in care and to provide insight into disease pathogenesis and therapeutic opportunities. Angiotensin-converting enzyme 2 (ACE2), CD26, CD147, and neuropilin-1 (NRP-1) are some of the key molecules identified as contributing to the entry of coronaviruses such as SARS-CoV-2 into human cells. 4 There is immense interest in these and viral entry facilitating proteases such as transmembrane serine protease 2 (TMPRSS2) as therapeutic targets for limiting infection. Soluble forms of viral entry receptors have been postulated to act as viral traps for SARS-CoV-2 by preventing interaction of the virus with membrane-bound forms. 5 We predict that elevation of these at the maternal-fetal interface contributes to the lack of vertical transmission and limits severity of disease from SARS-CoV-2 infection in the fetus and neonate. Soluble (s) ACE2, sCD26, sCD147, and sNRP-1 are elevated at the maternal-fetal interface. Figure 1B) . The blots were checked for non-specific binding by treating the membranes with secondary antibodies only; this revealed no non-specific bands. All samples were rich in the molecules of interest; BM had significantly higher sACE2 and sNRP-1 but lower sCD26 than AF ( Figure 1A ). Comparable levels of these soluble receptors in adult plasma are denoted by the dashed lines on the graphs. These average markers are from analysis of adult plasma concurrently using the same immunoassay. Different isoforms of sACE2, sCD26, and sCD147 existed in AF compared with BM ( Figure 1B) and might provide information about the origins of soluble forms of these mediators 6 and dictate their biological function. 7 For example, the shorter isoform of ACE2 lacks SARS-CoV-2 spike high-affinity binding sites 7 so AF sACE2 might be less efficient in acting as a viral decoy. These results suggest that both AF and BM are rich in soluble forms of at least some of the molecules that regulate SARS-CoV-2 host cell entry and could help protect the fetus and neonate from infection by acting as decoy receptors and contributing to innate immune protection in the gastrointestinal and respiratory tracts ( Figure 1C ). Such a mechanism might also be relevant for other viral infections. Future F I G U R E 1 Presence of soluble SARS-CoV-2 host cell entry-associated molecules in amniotic fluid (AF) and breastmilk (BM) at 2 and 6 weeks postpartum. (A) Soluble molecules (ACE2, CD26, CD147, and NRP-1) were measured in AF and BM using ELISAs. (B) The presence of these soluble molecules was confirmed with Western blotting, and isoforms were identified. (C) The presence of these soluble molecules in AF and BM which the baby ingests and aspirates may confer resistance to SARS-CoV-2 infection and/or severe COVID-19 (the images in (C) were created with BioRender) The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 A novel form of dipeptidylpeptidase iv found in human serum: isolation, characterization, and comparison with t lymphocyte membrane dipeptidylpeptidase IV (CD26) A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection Links between CD147 function, glycosylation, and caveolin-1 Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19 Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure